Holen Sie sich die Stockscreener-App
1.59
1.27%
0.02
Schlusskurs vom Vortag:
$1.57
Offen:
$1.55
24-Stunden-Volumen:
503.25K
Relative Volume:
0.69
Marktkapitalisierung:
$70.86M
Einnahmen:
$19.94M
Nettoeinkommen (Verlust:
$-37.37M
KGV:
-1.252
EPS:
-1.27
Netto-Cashflow:
$-33.38M
1W Leistung:
-3.64%
1M Leistung:
-3.05%
6M Leistung:
-40.89%
1J Leistung:
-44.79%
1-Tages-Spanne:
$1.49
$1.63
1-Wochen-Bereich:
$1.38
$1.72
52-Wochen-Spanne:
$1.38
$8.1939
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Vergleichen Sie HOWL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.59 | 70.86M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-24 | Eingeleitet | Wedbush | Outperform |
| 2023-06-06 | Fortgesetzt | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
Werewolf Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com UK
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Drops By 6.1% - Defense World
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1% - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology stock's potential amid clinical trials - Investing.com Australia
HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times
Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India
Werewolf Therapeutics stock hits 52-week low at $1.62 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock holds buy rating amid investor concerns over cytokine therapies By Investing.com - Investing.com Canada
HC Wainwright Reaffirms "Buy" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat
PFM Health Sciences, LP Increases Stake in Werewolf Therapeutics Inc - GuruFocus.com
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia
What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat
Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Quarterly 10-Q Report - Quartz
Werewolf Therapeutics reports promising trial data for cancer drug - Investing.com
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical - GlobeNewswire
Werewolf's WTX-330 Shows Promise in Phase 1 Trial: Melanoma Patient Responds to Novel IL-12 Therapy | HOWL Stock News - StockTitan
Werewolf Therapeutics Reports Breakthrough Cancer Trial Results Despite $16.7M Loss | HOWL Stock News - StockTitan
Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease - BioWorld Online
Werewolf Therapeutics expands pipeline with new IBD candidate By Investing.com - Investing.com South Africa
Werewolf Therapeutics expands pipeline with new IBD candidate - Investing.com
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases - The Manila Times
Werewolf Therapeutics Announces Promising New Development - GlobeNewswire
WisdomTree Inc (NYSE: WT): Blank Check On Growth? - Stocks Register
Werewolf To Provide Clinical Update On WTX-330 - RTTNews
Werewolf Therapeutics Inc (NASDAQ: HOWL) Could Pass $12 In One Year Stock Forecast - Stocks Register
Social Security Just Released the 2025 COLA. Here's What It Means for Those Receiving Spousal Benefits. - Yahoo! Voices
Could Buying Apple Stock Today Set You Up for Life? - Yahoo! Voices
Is Summit Therapeutics Inc. (SMMT) the Best QQQ Stock to Buy According to Analysts? - Yahoo Finance
Lyft is working on a ‘service animal opt-in feature’ for passengers - Yahoo! Voices
Hammond packaging facility to get $35M upgrade - Yahoo! Voices
2 Game-Changing Artificial Intelligence (AI) Stocks to Buy Right Now (Hint: Not Nvidia) - Yahoo! Voices
Poland’s stunning success should be discomforting for Britain - Yahoo! Voices
Every UPS Investor Should Keep an Eye on This Number - Yahoo! Voices
Billionaire Philippe Laffont Just Increased His Position by 139% in This Data Center Opportunity (Hint: It's Not Nvidia) - Yahoo! Voices
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Cut the state to get growing - Yahoo! Voices
‘It’s huge’: Striking Boeing workers near deal - Yahoo! Voices
National Association of Black Accountants’ St. Louis Chapter honors 50 years of community impact - Yahoo! Voices
Voya Financial Reports $341 Billion AUM Milestone - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
mRNA licensing agreements surge 800% amid GSK lawsuits - Yahoo Finance
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc - Yahoo Finance
State Street Corp's Strategic Reduction in Viking Therapeutics Holdings - Yahoo Finance
Nvidia to be the first company to hit $4T market cap: Lumida CEO - Yahoo Finance
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):